Crohn’s disease
Clinical research in Crohn’s disease is centred on patients with ongoing inflammatory activity and previous treatment loss of response, with attention to maintaining control over gastrointestinal inflammation and mucosal disease activity.
- Long-term disease control
- Biologic treatment optimisation
- Loss of response management
Work in this area includes interest in sustained outcomes with biologic therapy and treatment adjustments in patients with persistent inflammatory bowel disease.
Ulcerative colitis and unclassified inflammatory bowel disease
Research activity also extends to ulcerative colitis and inflammatory bowel disease type unclassified, reflecting a broader focus on chronic intestinal inflammation and related clinical outcomes across IBD subtypes.
- Inflammatory bowel disease subtypes
- Clinical remission maintenance
- Biological disease monitoring
The sponsor’s trial portfolio includes comparisons relevant to patients whose disease course requires ongoing assessment of symptom control and biological response.
Biologic therapy optimisation
The funded studies focus on optimisation of established monoclonal antibody treatments, with interest in how changes in administration schedules affect clinical efficacy and biological outcomes.
- Ustekinumab
- Infliximab
- Subcutaneous maintenance therapy
This area highlights continued evaluation of advanced therapeutics used in chronic immune-mediated bowel disease.
Clinical and biological remission
Another key interest is the preservation of clinical remission alongside biological remission, with research examining how patients respond after switching between intravenous and subcutaneous treatment approaches.
- Remission maintenance
- Treatment switching
- Outcome comparison
These studies address practical questions in the management of chronic inflammatory bowel disorders within specialist care settings.
